Your session is about to expire
← Back to Search
Imiquimod + Pembrolizumab for Skin Cancer
Study Summary
This trial studies the side effects and efficacy of imiquimod and pembrolizumab in treating patients with stage IIIB-IV melanoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any severe illnesses or social situations that would stop me from following the study's requirements.I haven't used any experimental treatments or devices for my cancer in the last 4 weeks.Women who can have children must have a negative pregnancy test.I am currently breastfeeding.I have had pneumonitis treated with steroids or have it now.I have been treated for an autoimmune disease in the last 2 years.I have had a heart attack in the last 6 months or have heart failure needing constant treatment.I have an active tuberculosis infection.I haven't had cancer treatment with monoclonal antibodies in the last 4 weeks or have recovered from their side effects.I have not received a live vaccine in the last 30 days.I am currently on medication for an infection.I have not been treated with pembrolizumab or similar drugs for my metastatic disease.I am willing to provide a tissue sample from my skin lesion for testing.I have an active hepatitis B or C infection.I am of childbearing age and do not plan to use birth control.I am fully active or restricted in physically strenuous activity but can do light work.I haven't had cancer treatment or fully recovered from its side effects in the last 2 weeks.My cancer is at a stage that cannot be removed by surgery.You have a disease that can be measured using specific guidelines.I have been diagnosed with HIV.My cancer has spread to my brain or spinal cord.I have a skin lesion that can be treated with a cream.Your blood tests should show normal levels of white blood cells, platelets, hemoglobin, and certain other substances in your blood.I have another cancer besides the one being treated, which has gotten worse or needs treatment.You are allergic to pembrolizumab or any of its ingredients.I have been treated with drugs targeting PD-1, PD-L1, or PD-L2.
- Group 1: Treatment (pembrolizumab, imiquimod)
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the scale of participation in this research project?
"As of now, this study is not currently enrolling. It was initially published in December 2017 and last edited on October 7th 2022; however, there are 832 studies recruiting participants with stage IV cutaneous melanoma AJCC V6 and V7 as well as 978 trials utilizing Pembrolizumab actively seeking volunteers."
Are there any available openings for individuals seeking to join this clinical trial?
"This research project is not presently looking for new participants. It was first publicized on December 20th 2017 and most recently edited October 7th 2022. However, if you are searching for alternatives, 832 clinical trials with Stage IV cutaneous melanoma AJCC v6 & V7 are actively recruiting as well as 978 experiments using Pembrolizumab."
What medical ailments are most commonly treated with Pembrolizumab?
"Pembrolizumab is typically utilized to treat non-operable melanoma, but it also has the potential to alleviate symptoms associated with microsatellite instability high and a heightened risk of recurrence."
What other research has been conducted regarding the use of Pembrolizumab?
"At present, there are 978 clinical trials pertaining to Pembrolizumab in active progress and 127 of those studies have progressed past the second phase. Although numerous investigations are conducted out of Nashville, Tennessee, a total of 36006 research centres around the world are currently exploring this novel therapy."
Share this study with friends
Copy Link
Messenger